{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:49:04Z","timestamp":1789742944870,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006470","name":"Aristotle University of Thessaloniki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To synthesize existing evidence on adverse events, complications, and unfavorable outcomes of current treatment modalities for treatment-requiring retinopathy of prematurity (TR-ROP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PubMed, Cochrane Central Register of Controlled Trials, Scopus, EMBASE, Trip Database, and the gray literature available were searched. Randomized Clinical Trials and observational studies comparing the adverse events of intravitreal anti-VEGF injections (bevacizumab, ranibizumab, aflibercept, pegaptanib, conbercept) and laser photocoagulation (LPC) as treatment modalities for infants with TR-ROP were included. The main outcomes compared between the two treatment modalities were: 1. Refractive Errors and Biometry Parameters, 2. Adverse events, complications, and unfavorable outcomes, 3. Disease Recurrence\/Disease Regression\/Need for retreatment, 4. Neurodevelopmental Outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Higher quality studies concluded that LPC leads to greater rates of myopia than intravitreal anti-VEGF treatment while the rate of adverse events and of unfavorable neurodevelopmental outcomes is similar. However, there was controversy among the included studies concerning the rate of ROP recurrence between intravitreal anti-VEGF injections and LPC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There is need for future primary studies assessing the adverse events of intravitreal anti-VEGF injections compared with LPC as treatment modalities for infants with TR-ROP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10792-022-02480-6","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:51:55Z","timestamp":1665402715000},"page":"1027-1062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-545X","authenticated-orcid":false,"given":"Georgios N.","family":"Tsiropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini K.","family":"Seliniotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-8799","authenticated-orcid":false,"given":"Anna-Bettina","family":"Haidich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8362-6794","authenticated-orcid":false,"given":"Nikolaos","family":"Ziakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-022X","authenticated-orcid":false,"given":"Asimina","family":"Mataftsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"2480_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.semperi.2019.05.001","volume":"43","author":"BA Darlow","year":"2019","unstructured":"Darlow BA, Gilbert C (2019) Retinopathy of prematurity: a world update. Semin Perinatol 43:315\u2013316. https:\/\/doi.org\/10.1053\/j.semperi.2019.05.001","journal-title":"Semin Perinatol"},{"key":"2480_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ajo.2020.05.025","volume":"218","author":"ME Hartnett","year":"2020","unstructured":"Hartnett ME (2020) Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor. Am J Ophthalmol 218:208\u2013213. https:\/\/doi.org\/10.1016\/j.ajo.2020.05.025","journal-title":"Am J Ophthalmol"},{"key":"2480_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/archopht.1988.01060130509025","volume":"106","author":"W Tasman","year":"1988","unstructured":"Tasman W (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 106:463\u2013464","journal-title":"Arch Ophthalmol"},{"key":"2480_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0161-6420(01)00540-1","volume":"108","author":"WV Good","year":"2001","unstructured":"Good WV, Hardy RJ (2001) Guest editorial: the multicenter study of early treatment for retinopathy of prematurity (ETROP). Ophthalmology 108:1013\u20131014. https:\/\/doi.org\/10.1016\/S0161-6420(01)00540-1","journal-title":"Ophthalmology"},{"key":"2480_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"2480_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF et al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394:1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"2480_CR7","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"2480_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"2480_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"2480_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3341\/kjo.2019.0011","volume":"33","author":"HG Kang","year":"2019","unstructured":"Kang HG, Kim TY, Han J, Han S-H (2019) Refractive outcomes of 4-year-old children after intravitreal anti-vascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity. Korean J Ophthalmol 33:272. https:\/\/doi.org\/10.3341\/kjo.2019.0011","journal-title":"Korean J Ophthalmol"},{"key":"2480_CR11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","volume":"42","author":"EU Kabata\u015f","year":"2017","unstructured":"Kabata\u015f EU, Kurtul BE, Alt\u0131ayl\u0131k \u00d6zer P, Kabata\u015f N (2017) Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res 42:1054\u20131058. https:\/\/doi.org\/10.1080\/02713683.2016.1264607","journal-title":"Curr Eye Res"},{"key":"2480_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","volume":"42","author":"M Gunay","year":"2017","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y (2017) Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res 42:462\u2013469. https:\/\/doi.org\/10.1080\/02713683.2016.1196709","journal-title":"Curr Eye Res"},{"key":"2480_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.joco.2018.10.008","volume":"31","author":"R Roohipoor","year":"2019","unstructured":"Roohipoor R, Torabi H, Karkhaneh R, Riazi-Eafahani M (2019) Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity. J Curr Ophthalmol 31:61\u201365. https:\/\/doi.org\/10.1016\/j.joco.2018.10.008","journal-title":"J Curr Ophthalmol"},{"key":"2480_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol"},{"key":"2480_CR15","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","volume":"39","author":"K Raghuram","year":"2019","unstructured":"Raghuram K, Isaac M, Yang J, AlAli A, Mireskandari K, Ly LG et al (2019) Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol 39:1300\u20131308. https:\/\/doi.org\/10.1038\/s41372-019-0420-z","journal-title":"J Perinatol"},{"key":"2480_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","volume":"104","author":"YC Chen","year":"2020","unstructured":"Chen YC, Chen SN (2020) Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol 104:691\u2013696. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314610","journal-title":"Br J Ophthalmol"},{"key":"2480_CR17","doi-asserted-by":"crossref","unstructured":"Therani N, Isaac M, Raghuram K, Mireskandari K, Shah P (2019) Neurodevelopmental and visual outcomes in infants with retinopathy of prematurity treated with bevacizumab versus laser. In: 2019 AAPOS abstract book, pp 240","DOI":"10.1016\/j.jaapos.2019.08.204"},{"key":"2480_CR18","doi-asserted-by":"crossref","unstructured":"Manuchian S, Isaac M, Mireskandari K, Tehrani N, Vincer M, Hatchette J et al (2019) Binocularity outcomes following treatment for retinopathy of prematurity. In: 2019 AAPOS abstract book, pp 244","DOI":"10.1016\/j.jaapos.2019.08.156"},{"key":"2480_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","volume":"2","author":"R Roohipoor","year":"2018","unstructured":"Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Farahani AD, Khodabandeh A, Adib NE et al (2018) Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retin 2:942\u2013948. https:\/\/doi.org\/10.1016\/j.oret.2018.01.017","journal-title":"Ophthalmol Retin"},{"key":"2480_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","volume":"192","author":"YS Lee","year":"2018","unstructured":"Lee YS, See LC, Chang SH, Wang NK, Hwang YS, Lai CC et al (2018) Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192:20\u201330. https:\/\/doi.org\/10.1016\/j.ajo.2018.05.002","journal-title":"Am J Ophthalmol"},{"key":"2480_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bjophthalmol-2016-308375","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C et al (2017) Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol 101:365\u2013370. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308375","journal-title":"Br J Ophthalmol"},{"key":"2480_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.9734\/OR\/2015\/13281","volume":"3","author":"L Kong","year":"2015","unstructured":"Kong L, Dinh K, Schechet S, Coats D, Voigt R, Demny A et al (2015) Comparison of ocular and developmental outcomes in laser-and bevacizumab-treated infants with retinopathy of prematurity. Ophthalmol Res An Int J 3:13\u201322. https:\/\/doi.org\/10.9734\/OR\/2015\/13281","journal-title":"Ophthalmol Res An Int J"},{"key":"2480_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2298\/VSP150831191V","volume":"74","author":"MS Vujanovi\u0107","year":"2017","unstructured":"Vujanovi\u0107 MS, Stankovi\u0107-Babi\u0107 GL, Oros A, Zlatanovi\u0107 GD, Jovanovi\u0107 P, Ceki\u0107 SP et al (2017) Refractive errors in premature infants with retinopathy of prematurity after anti-vascular endothelial growth factor (anti-VEGF) therapy. Vojnosanit Pregl 74:323\u2013328. https:\/\/doi.org\/10.2298\/VSP150831191V","journal-title":"Vojnosanit Pregl"},{"key":"2480_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.oftal.2016.12.007","volume":"92","author":"M Lolas","year":"2017","unstructured":"Lolas M, Tuma A, Zanolli M, Agurto R, Stevenson R, Ossand\u00f3n D (2017) Anatomical and refractive outcomes in patients with treated retinopathy of prematurity. Arch Soc Esp Oftalmol 92:472\u2013476. https:\/\/doi.org\/10.1016\/j.oftal.2016.12.007","journal-title":"Arch Soc Esp Oftalmol"},{"key":"2480_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/09273972.2016.1159232","volume":"24","author":"M Gunay","year":"2016","unstructured":"Gunay M, Sekeroglu MA, Bardak H, Celik G, Esenulku CM, Hekimoglu E et al (2016) Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity. Strabismus 24:84\u201388. https:\/\/doi.org\/10.3109\/09273972.2016.1159232","journal-title":"Strabismus"},{"key":"2480_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161692","volume":"11","author":"M Gunay","year":"2016","unstructured":"Gunay M, Celik G, Tuten A, Karatekin G, Bardak H, Ovali F (2016) Characteristics of severe retinopathy of prematurity in infants with birth weight above 1500 grams at a referral center in Turkey. PLoS ONE 11:e0161692. https:\/\/doi.org\/10.1371\/journal.pone.0161692","journal-title":"PLoS ONE"},{"key":"2480_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5935\/0004-2749.20150079","volume":"78","author":"M Gunay","year":"2015","unstructured":"Gunay M, Celik G, Gunay BO, Aktas A, Karatekin G, Ovali F (2015) Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 78:300\u2013304. https:\/\/doi.org\/10.5935\/0004-2749.20150079","journal-title":"Arq Bras Oftalmol"},{"key":"2480_CR28","first-page":"4321","volume":"56","author":"AL Li","year":"2015","unstructured":"Li AL, Rahman EZ, Voigt RG, Coats DK, Steinkuller PG, Kong L (2015) Long-term vision and neurodevelopmental outcomes in laser and bevacizumab-treated infants with retinopathy of prematurity. Investig Ophthalmol Vis Sci 56:4321","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2480_CR29","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122:1008\u20131015. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.017","journal-title":"Ophthalmology"},{"key":"2480_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000439182","volume":"234","author":"HK Kuo","year":"2015","unstructured":"Kuo HK, Sun IT, Chung MY, Chen YH (2015) Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotherapy. Ophthalmologica 234:211\u2013217. https:\/\/doi.org\/10.1159\/000439182","journal-title":"Ophthalmologica"},{"key":"2480_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","volume":"19","author":"M Isaac","year":"2015","unstructured":"Isaac M, Mireskandari K, Tehrani N (2015) Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS 19:140\u2013144. https:\/\/doi.org\/10.1016\/j.jaapos.2015.01.009","journal-title":"J AAPOS"},{"key":"2480_CR32","first-page":"985","volume":"56","author":"M Isaac","year":"2015","unstructured":"Isaac M, Mireskandari K, Tehrani N (2015) Outcomes following treatment of type 1 retinopathy of prematurity with bevacizumab versus laser: two year follow up. Investig Ophthalmol Vis Sci 56:985","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2480_CR33","first-page":"973","volume":"56","author":"A Warren","year":"2015","unstructured":"Warren A, Warren K, Weatherstone K (2015) Bevacizumab (AvastinTM) as a treatment alternative for threshold retinopathy of prematurity (ROP). Investig Ophthalmol Vis Sci 56:973","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2480_CR34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB (2013) Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155:1119-1124.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.01.014","journal-title":"Am J Ophthalmol"},{"key":"2480_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/archophthalmol.2012.1","volume":"130","author":"BC Harder","year":"2012","unstructured":"Harder BC, von Baltz S, Schlichtenbrede FC, Jonas JB (2012) Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol 130:800\u2013801. https:\/\/doi.org\/10.1001\/archophthalmol.2012.1","journal-title":"Arch Ophthalmol"},{"key":"2480_CR36","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1136\/bjophthalmol-2018-312272","volume":"103","author":"HG Kang","year":"2019","unstructured":"Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC et al (2019) Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety. Br J Ophthalmol 103:1332\u20131336. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312272","journal-title":"Br J Ophthalmol"},{"key":"2480_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH et al (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218\u2013226. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.005","journal-title":"Ophthalmology"},{"key":"2480_CR38","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M et al (2016) Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol 94:e417\u2013e420. https:\/\/doi.org\/10.1111\/aos.13008","journal-title":"Acta Ophthalmol"},{"key":"2480_CR39","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M et al (2017) Comparison of intravitreal injection of ranibizumab versus laser therapy for Zone II treatment-requiring retinopathy of prematurity. Retina 37:710\u2013717. https:\/\/doi.org\/10.1097\/IAE.0000000000001241","journal-title":"Retina"},{"key":"2480_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4103\/tjo.tjo_69_18","volume":"8","author":"M Blair","year":"2018","unstructured":"Blair M, Gonzalez JMG, Snyder L, Schechet S, Greenwald M, Shapiro M et al (2018) Bevacizumab or laser for aggressive posterior retinopathy of prematurity. Taiwan J Ophthalmol 8:243\u2013248. https:\/\/doi.org\/10.4103\/tjo.tjo_69_18","journal-title":"Taiwan J Ophthalmol"},{"key":"2480_CR41","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00347-018-0701-5","volume":"115","author":"JM Walz","year":"2018","unstructured":"Walz JM, Bemme S, Reichl S, Akman S, Breu\u00df H, S\u00fcsskind D et al (2018) Treated cases of retinopathy of prematurity in Germany: 5-year data from the Retina.net ROP registry. Ophthalmologe 115:476\u2013488. https:\/\/doi.org\/10.1007\/s00347-018-0701-5","journal-title":"Ophthalmologe"},{"key":"2480_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12886-019-1067-4","volume":"19","author":"J Lyu","year":"2019","unstructured":"Lyu J, Zhang Q, Chen C, Xu Y, Ji X, Zhao P (2019) Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study. BMC Ophthalmol 19:60. https:\/\/doi.org\/10.1186\/s12886-019-1067-4","journal-title":"BMC Ophthalmol"},{"key":"2480_CR43","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaapos.2019.05.014","volume":"23","author":"PK Shah","year":"2019","unstructured":"Shah PK, Subramanian P, Venkatapathy N, Chan RVP, Chiang MF, Campbell JP (2019) Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention. J AAPOS 23:264. https:\/\/doi.org\/10.1016\/j.jaapos.2019.05.014","journal-title":"J AAPOS"},{"key":"2480_CR44","doi-asserted-by":"crossref","unstructured":"Zhang M, Blair MP, Rodriguez SH (2019) Two-year ocular and neurodevelopmental outcomes among infants treated for retinopathy of prematurity using a commercial claims database. In: 2019 AAPOS abstract book, pp 237","DOI":"10.1016\/j.jaapos.2019.08.240"},{"key":"2480_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00417-016-3443-6","volume":"255","author":"EA Sukgen","year":"2017","unstructured":"Sukgen EA, Ko\u00e7luk Y (2017) Treatment for stage 4A retinopathy of prematurity: laser and\/or ranibizumab. Graefe\u2019s Arch Clin Exp Ophthalmol 255:263\u2013269. https:\/\/doi.org\/10.1007\/s00417-016-3443-6","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2480_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jaapos.2019.05.013","volume":"23","author":"GP Barry","year":"2019","unstructured":"Barry GP, Tauber KA, Fisher M, Greenberg S, Zobal-Ratner J, Binenbaum G (2019) Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab. J AAPOS 23:260. https:\/\/doi.org\/10.1016\/j.jaapos.2019.05.013","journal-title":"J AAPOS"},{"key":"2480_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/dmcn.71_14017","volume":"60","author":"C Peyton","year":"2018","unstructured":"Peyton C, Rodriquez S, Andrews B, Schreiber M, Wroblewski K, Msall M (2018) Neurodevelopmental outcomes after extreme prematurity comparing bevacizumab to laser surgery for type 1 retinopathy of prematurity. Dev Med Child Neurol 60:47. https:\/\/doi.org\/10.1111\/dmcn.71_14017","journal-title":"Dev Med Child Neurol"},{"key":"2480_CR48","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","volume":"40","author":"KP Ling","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK, Chao AN, Chen KJ, Chen TL et al (2020) Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina 40:1793\u20131803. https:\/\/doi.org\/10.1097\/IAE.0000000000002663","journal-title":"Retina"},{"key":"2480_CR49","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1111\/aos.12339","volume":"92","author":"S Moran","year":"2014","unstructured":"Moran S, O\u2019Keefe M, Hartnett C, Lanigan B, Murphy J, Donoghue V (2014) Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmol 92:e496\u2013e497. https:\/\/doi.org\/10.1111\/aos.12339","journal-title":"Acta Ophthalmol"},{"key":"2480_CR50","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.12659\/MSM.897095","volume":"22","author":"SD Nicoar\u0103","year":"2016","unstructured":"Nicoar\u0103 SD, \u0218tef\u0103nu\u0163 AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit 22:1192\u20131209. https:\/\/doi.org\/10.12659\/MSM.897095","journal-title":"Med Sci Monit"},{"key":"2480_CR51","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","volume":"123","author":"BC Toy","year":"2016","unstructured":"Toy BC, Schachar IH, Tan GSW, Moshfeghi DM (2016) Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmology 123:2166\u20132175. https:\/\/doi.org\/10.1016\/j.ophtha.2016.06.055","journal-title":"Ophthalmology"},{"key":"2480_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE 11:e0148019. https:\/\/doi.org\/10.1371\/journal.pone.0148019","journal-title":"PLoS ONE"},{"issue":"3","key":"2480_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230678","volume":"15","author":"M Arima","year":"2020","unstructured":"Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E et al (2020) Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE 15(3):e0230678. https:\/\/doi.org\/10.1371\/journal.pone.0230678","journal-title":"PLoS ONE"},{"key":"2480_CR54","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3928\/23258160-20180129-07","volume":"49","author":"TA Chen","year":"2018","unstructured":"Chen TA, Schachar IH, Moshfeghi DM (2018) Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina 49:126\u2013131. https:\/\/doi.org\/10.3928\/23258160-20180129-07","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2480_CR55","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN et al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137:e20153218. https:\/\/doi.org\/10.1542\/peds.2015-3218","journal-title":"Pediatrics"},{"key":"2480_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","volume":"22","author":"KA Kennedy","year":"2018","unstructured":"Kennedy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group (2018) Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS 22:61-65.e1. https:\/\/doi.org\/10.1016\/j.jaapos.2017.10.006","journal-title":"J AAPOS"},{"key":"2480_CR57","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ et al (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56:956\u2013961. https:\/\/doi.org\/10.1167\/iovs.14-15842","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2480_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5830\/CVJA-2019-058","volume":"31","author":"E Cilsal","year":"2020","unstructured":"Cilsal E, Sukgen EA (2020) Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser. Cardiovasc J Afr 31:123\u2013129","journal-title":"Cardiovasc J Afr"},{"key":"2480_CR59","doi-asserted-by":"crossref","unstructured":"Barry G, Tauber K, Afroze F, Finuncane E, Greenberg SH, Oechsner H et al (2019) A comparison of respiratory outcomes after treatment for retinopathy of prematurity (ROP) with pan-retinal photocoagulation (PRP) or bevacizumab. In: 2019 AAPOS abstract book, pp 238","DOI":"10.1016\/j.jaapos.2019.08.063"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02480-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02480-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02480-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T02:08:46Z","timestamp":1679969326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02480-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["2480"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02480-6","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No consent to participate was needed as the respective study is a systematic review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No consent to publish was needed as the respective study is a systematic review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"No ethics approval was needed as the respective study is a systematic review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}